Today: 8 June 2026
Why XCF Global stock is moving today: SAFX rises after Bank of America mandate, Soule discloses 49.6% stake
14 January 2026
2 mins read

Why XCF Global stock is moving today: SAFX rises after Bank of America mandate, Soule discloses 49.6% stake

New York, Jan 14, 2026, 08:21 EST — Premarket

  • SAFX shares rise in premarket after XCF tapped Bank of America to explore financing for a Nevada expansion
  • A new Schedule 13D shows Randy Soule and Encore DEC hold 78.9 million shares, or 49.6% of the class
  • Traders are also watching a Nasdaq minimum-bid deadline that runs to June 8

Shares of XCF Global (SAFX) were up about 11.5% in premarket trading on Wednesday after the sustainable aviation fuel maker said it was weighing funding options for a second plant in Nevada. The company has pegged the New Rise Reno 2 build at roughly $300 million, with an output jump that could double capacity to about 80 million gallons a year.

The timing matters because XCF is still proving it can turn one operating site into a repeatable build-out. For a small, thinly traded name, the next financing package is the story — it tells investors whether “Reno 2” is a plan or a shovel-ready project.

It also lands while the stock sits deep below $1, leaving little room for mishaps. Any new debt, export-backed structure, or equity-linked paper is likely to show up fast in the share count, the trading tape, or both.

XCF said it had engaged Bank of America to help structure potential debt financing that could qualify for export credit agency programmes, which are government-backed tools that can lower risk for lenders. The company also pointed to a non-binding memorandum of understanding, or MOU, with BGN INT US LLC aimed at building distribution and offtake frameworks in Europe and the Middle East, and warned there was no assurance any financing deal would be completed or on what terms. Chief executive Chris Cooper said “expanding SAF production has never been more critical.” ACCESS Newswire

A separate Schedule 13D filed on Tuesday showed Randy Soule and his construction and engineering firm Encore DEC beneficially owned 78.9 million shares, representing 49.6% of XCF’s Class A common stock. The filing said the shares were obtained by converting $28 million of invoices payable to Encore into XCF stock, and added the reporting persons did not plan to pursue major corporate actions “at this time” but reserved the right to do so. StreetInsider.com

That filing cuts two ways for the market. It highlights a large insider-linked position and a stated holding period, but it also underlines how the company is settling bills — and how quickly paper can turn into stock in capital-hungry projects.

In earlier disclosures, XCF said it had received a Nasdaq notice for failing to meet the exchange’s minimum bid-price requirement and had until June 8, 2026 to regain compliance. The company has also described non-binding talks with Southern Energy Renewables and carbon-management firm DevvStream on an arrangement tied to carbon credits and SAF production.

The risk case is straightforward: financing can stall, export-credit structures can take time, and the Reno 2 plan can slip if lenders push back on terms. A stock that trades in pennies also faces sharp swings, and any fresh equity-linked funding could hit holders hard if it comes with discounts or warrants.

Investors will be watching for any definitive financing package, and whether the BGN framework turns into signed offtake or distribution agreements that lenders can underwrite. Just as closely, they will watch whether SAFX can climb back above $1 long enough to clear Nasdaq’s clock ahead of June 8.

Stock Market Today

  • How to Buy SpaceX Stock on Its IPO Day: Key Details for Investors
    June 8, 2026, 10:09 AM EDT. SpaceX is set to go public on Nasdaq on June 12, aiming to raise $75 billion in what would be the largest IPO ever. The IPO price is $135 per share, available mainly to select investors through brokers including Robinhood, SoFi, Charles Schwab, Fidelity, and E*TRADE. Public investors can buy shares under ticker SPCX when trading begins, using market orders for immediate purchase or limit orders to control price. However, acquiring IPO-priced shares isn't guaranteed and depends on broker rules and allocation. For those wary of direct investment risks in the high-reward space sector, exposure via exchange-traded funds (ETFs) with SpaceX holdings is an alternative option.

Latest articles

Corning Wins Amazon AI Fiber Deal; GLW Faces Next Hurdle

Corning Wins Amazon AI Fiber Deal; GLW Faces Next Hurdle

8 June 2026
Amazon’s new multibillion-dollar supply deal makes Corning a key fiber provider for U.S. data centers, but with shares up 305% in 12 months and investors already pricing in big AI wins, the stock was little changed at $177.58 premarket as risks of factory delays and high expectations loom.
BlackBerry Shares Stall After QNX Push

BlackBerry Stock Moves in Pre-Market Ahead of June Test

8 June 2026
BlackBerry’s U.S. shares rose 2.34% in premarket trading to $9.63 after Friday’s 8.99% drop, but with analyst targets averaging just $4.98, investors are betting on QNX growth and secure-communications wins ahead of June 25 earnings; any disappointment could hit the stock hard.
Micron Technology Stock Surges as AI Memory Shortage Puts MU at Center of Chip Rally

Micron Shares Edge Up in Premarket; Investors Await Next AI Test

8 June 2026
Micron surged 8.2% to $935.07 in Nasdaq premarket after Friday’s $127 billion rout, as investors cheered Nvidia’s confirmation it will keep sourcing high-bandwidth memory from Micron and Samsung, easing fears SK Hynix would become exclusive supplier; Cantor Fitzgerald raised its price target to $1,500, with Micron’s next earnings report due June 24.
Tango Therapeutics Stock Surges After Cancer Drug Shows 92% Response Rate

Tango Therapeutics Stock Surges After Cancer Drug Shows 92% Response Rate

8 June 2026
Tango shares soared up to 48% in premarket trading after reporting a 92% objective response rate and 90% six-month progression-free survival in a 12-patient pancreatic cancer trial, with plans to advance the vopimetostat-daraxonrasib combo to Phase 3 testing in first-line MTAP-deleted pancreatic cancer.
BHP stock ends higher as China’s iron ore surge meets merger talk — what’s next for ASX:BHP
Previous Story

BHP stock ends higher as China’s iron ore surge meets merger talk — what’s next for ASX:BHP

DAX record streak snaps as Frankfurt stocks slide; Bayer jumps 7%
Next Story

DAX record streak snaps as Frankfurt stocks slide; Bayer jumps 7%

Go toTop